Strata Critical Medical financials
$5.10−2.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $197.1M |
| Gross profit | $41.1M |
| Gross margin | 20.9% |
| Operating income | -$22.4M |
| Net income | $41.3M |
| Net margin | 21.0% |
| Diluted EPS | $0.50 |
| EBITDA | -$14.2M |
| Operating cash flow | -$48.9M |
| Free cash flow | -$58.5M |
| Diluted shares | 82.1M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $31.0M |
| Short-term investments | $30.3M |
| Total debt | $0.00 |
| Total assets | $325.5M |
| Total liabilities | $46.4M |
| Shareholders' equity | $279.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology